The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer

Jun Miyazaki, Koji Kawai, Hitoshi Hayashi, Mizuki Onozawa, Sadamu Tsukamoto, Naoto Miyanaga, Shiro Hinotsu, Toru Shimazui, Hideyuki Akaza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma. Methods: Eight patients with metastatic testicular cancer who had elevated β-hCG were treated with MAP. They included three refractory cases and two relapsed cases. An additional three patients received MAP as part of the induction therapy. The MAP therapy consisted of methotrexate (10 mg/m2) on days 1-5, actinomycin D (0.01 mg/kg) on days 1-5 and cisplatin (70 mg/m2) on day 1. Results: In all three refractory patients, MAP failed to achieve tumor marker normalization. However, the elevated tumor markers normalized after MAP in the two cases of relapse. Of these two, one patient relapsed again 7 months after MAP and was subsequently salvaged with high-dose chemotherapy. The other patient relapsed and died of the disease 30 months after receiving MAP. Of the three patients who received MAP as part of the induction chemotherapy, one with pure choriocarcinoma achieved tumor marker normalization after MAP and is still alive without disease progression. In the other two patients, MAP failed to achieve marker normalization and the patients received high-dose chemotherapy. The toxicities were mainly bone marrow suppression and mucositis, which were almost acceptable. Conclusions: The results demonstrated the limited efficacy of MAP as salvage therapy. In addition, the efficacy of MAP as part of induction chemotherapy was negligible. However, there might be some role for MAP as a salvage therapy for patients with pure choriocarcinoma.

Original languageEnglish
Pages (from-to)391-395
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • Actinomycin
  • Cisplatin
  • Methorexate
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Miyazaki, J., Kawai, K., Hayashi, H., Onozawa, M., Tsukamoto, S., Miyanaga, N., Hinotsu, S., Shimazui, T., & Akaza, H. (2003). The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. Japanese Journal of Clinical Oncology, 33(8), 391-395. https://doi.org/10.1093/jjco/hyg074